Mitsubishi Heavy Industrial Develops New Cancer Treatment Device
This article was originally published in PharmAsia News
Mitsubishi Heavy Industrial has developed a new X-ray cancer treatment device that scans and radiates affected areas. The equipment is jointly developed with Kyodo University and the Kobe-based Institute of Biomedical Research and Innovation and will be sold in Japan, the E.U. and the U.S. The device uses X-ray technology to scan cancer cells, processes information on the cancer position through computers, and then radiates the area with an oscillating X-ray head based on the processed information. Because of the high level of accuracy, Mitsubishi stated that the radiation therapy would reduce the occurrence of side effects and shorten treatment time. (Click here for more-Japanese language
You may also be interested in...
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
A proposed rule released last month by the US Department of Health and Human Services is the Trump administration’s “latest attempt to sabotage HHS programs,” wrote Jessica Schubel, a senior policy analyst for the Center on Budget and Policy Priorities. See what the policy expert said about it in her blog post here.
Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.